Rapport Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Rapport Therapeutics has a total shareholder equity of $323.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $331.1M and $8.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$320.66m |
| Equity | US$323.11m |
| Total liabilities | US$8.03m |
| Total assets | US$331.14m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RAPP's short term assets ($325.9M) exceed its short term liabilities ($7.1M).
Long Term Liabilities: RAPP's short term assets ($325.9M) exceed its long term liabilities ($931.0K).
Debt to Equity History and Analysis
Debt Level: RAPP is debt free.
Reducing Debt: RAPP had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RAPP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RAPP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.